ADVENZYMES

- Management reported Q1 FY27 with a softer start, showing 2% YoY revenue growth, a 10% YoY decline in EBITDA, and a 5% YoY decline in PAT, with EBITDA margin contracting from 30% to 27%. This was attributed to lower top-line realization, elevated energy costs, sales mix shift, and an additional INR 100 million sales reversal expected in Q2. - The company remains confident in achieving sustainable double-digit revenue growth and expects EBITDA margin to recover to approximately 30% for the full year. - The Board approved a share buyback of INR 697 million at a ceiling price of INR 500 per share via the open market route. - Advanced Enzyme Technologies acquired the remaining 4.28% stake in its subsidiary, JC Biotech, for INR 79.79 million, making it a wholly-owned subsidiary. - Planned CapEx for FY27 is INR 123 crore, with INR 50 crore allocated for R&D and the remainder for growth, as fermentation utilization has reached 70-75%. - The U.S. business is undergoing a strategic shift with a focus on branding to drive an expected 8-10% growth by year-end. - The biocatalysis segment is anticipated to show good growth in the second half of the year, with expansion into various industries. - Working capital cycle stood at 125-138 days as of June 30, 2026, with inventory at INR 190 crore, receivables at INR 131 crore, and payables at INR 41 crore.

- Board of Directors of Advanced Enzyme Technologies Ltd. approved an open market buyback of equity shares on August 08, 2026. - Max Buyback Price: ₹500 per share. - Max Buyback Size: ₹697 Crores for up to 1,394,000 shares, representing up to 10% of paid-up capital and free reserves.

- Audio recording of the conference call held on August 12, 2026, for the unaudited financial results for the quarter ended June 30, 2026, is available on the company's website. - The transcript of the conference call will be made available to the Stock Exchanges and uploaded on the website in due course.

- Board approved a buyback of equity shares up to ₹69.70 Crores. - Maximum Buyback Price: ₹500 per share, representing an approximately 58% premium over the closing market price on August 01, 2026. - Indicative maximum shares to be bought back: 1,394,000, via open market route. - The buyback is funded from internal accruals, free reserves, and cash balances, without using borrowed funds.

- Advanced Enzyme Technologies Ltd. has made a Public Announcement for the buyback of its equity shares, as approved in the Board Meeting on August 08, 2026. - The buyback offer will open on August 14, 2026. - The offer will close on the earlier of sixty-six Working Days (i.e., November 20, 2026), the company completing the buyback by deploying the maximum buyback size, or an earlier date determined by the Board.

- Q1 FY27 Consolidated Revenue ₹1,898Mn vs ₹1,859Mn (▲2% YoY) - EBITDA ₹510Mn vs ₹564Mn (▼10% YoY) - PAT ₹386Mn vs ₹404Mn (▼5% YoY) - EBITDA Margin 27% vs 30.33% (▼333bps)

- Q1 FY27 Consolidated Revenue ₹1,898Mn vs ₹1,859Mn (▲2% YoY) - EBITDA ₹510Mn vs ₹564Mn (▼10% YoY) - PAT ₹386Mn vs ₹404Mn (▼5% YoY) - EBITDA Margin 27% vs 30% (▼300bps)

- Q1 FY27 Consolidated Revenue ₹189.79 Cr vs ₹185.91 Cr (▲2.08% YoY) - EBITDA ₹50.96 Cr vs ₹56.43 Cr (▼9.69% YoY) - PAT ₹38.59 Cr vs ₹40.44 Cr (▼4.57% YoY) - EBITDA Margin 26.85% vs 30.35% (▼350bps) - Board approved a buyback of equity shares for up to ₹69.7 Cr at a maximum price of ₹500 per share via open market route. - Approved acquisition of the remaining 4.28% stake in JC Biotech Private Limited, making it a wholly-owned subsidiary. - Approved infusion of additional funds not exceeding ₹20 million into Advanced Nutrazyme Private Limited (WOS).

- Q1 FY27 Consolidated Revenue ₹189.79 Cr vs ₹185.91 Cr (▲2.08% YoY) - EBITDA ₹50.97 Cr vs ₹56.43 Cr (▼9.69% YoY) - PAT ₹38.59 Cr vs ₹40.44 Cr (▼4.57% YoY) - EBITDA Margin 26.86% vs 30.35% (▼349 bps) - Approved a buyback of fully paid-up equity shares at a price not exceeding ₹500/- per share for an aggregate amount not exceeding ₹69.70 Cr. - The buyback will involve a maximum of 1,394,000 shares (1.24% of paid-up capital) via the Open Market route. - Approved acquisition of the remaining 4.28% stake in JC Biotech Private Limited, making it a Wholly Owned Subsidiary. - Approved infusion of additional funds not exceeding ₹2 Cr into Advanced Nutrazyme Private Limited (WOS) via equity investment or inter-corporate deposit.

- Q1 FY27 Consolidated Revenue ₹189.79 Cr vs ₹185.91 Cr (▲2.08% YoY) - EBITDA ₹50.96 Cr vs ₹56.43 Cr (▼9.69% YoY) - PAT ₹37.09 Cr vs ₹39.93 Cr (▼7.10% YoY) - EBITDA Margin 26.85% vs 30.35% (▼350 bps) - Board approved a Buyback of equity shares via "Open Market" route at a price not exceeding ₹500/- per share, for an aggregate amount not exceeding ₹69.70 Cr. - Approved the acquisition of the remaining 4.28% stake in JC Biotech Private Limited for ₹7.98 Cr, making it a Wholly Owned Subsidiary. - Approved infusion of additional funds up to ₹2 Cr into Advanced Nutrazyme Private Limited, a Wholly Owned Subsidiary.

- Concall Schedule for Un-audited Financial Results for the quarter ended June 30, 2026 - Concall Date: Wednesday, August 12, 2026 - Concall Time: 04:00 p.m. IST

- The 37th Annual General Meeting (AGM) held on July 31, 2026, approved the re-appointment of Mr. Mukund Madhusudan Kabra as Whole Time Director for five years. - Mr. Pradip Bhailal Shah was appointed as an Independent Director for five consecutive years. - MSKA & Associates LLP were re-appointed as Statutory Auditors for a second five-year term.

- 37th Annual General Meeting held on July 31, 2026. All resolutions, including the declaration of a final dividend of ₹1.35 per equity share for the financial year ended March 31, 2026, were passed with the requisite majority.

- 37th Annual General Meeting (AGM) of Advanced Enzyme Technologies Ltd. was held on July 31, 2026. - Members approved the Audited Financial Statements for the year ended March 31, 2026. - A final dividend of ₹1.35/- per Equity Share was declared for FY 2025-26. - Resolutions for re-appointment of directors, auditors, and approval of related party transactions were also passed.

- Intimation of the 37th Annual General Meeting (AGM) to be held on Friday, July 31, 2026, at 10:00 AM (IST) via Video Conferencing/Other Audio Visual Means. - Integrated Annual Report for FY 2025-26 and AGM Notice are accessible via company website web-links and QR codes. - Shareholders holding physical shares are reminded to update their KYC details; dividends, if declared, will be paid electronically.

- Filing of the Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The report details the company's ESG performance, including business activities, employee data, and identifies material risks and opportunities related to climate, environment, supply chain, and data privacy.

- Notice of 37th Annual General Meeting (AGM) to be held on Friday, July 31, 2026, at 10:00 a.m. (IST) via Video Conference/OAVM. - Agenda includes adoption of FY26 financial statements and declaration of a final dividend of ₹1.35 per Equity Share. - Key re-appointments: Ms. Rasika Rathi (Director), M/s. MSKA & Associates LLP (Statutory Auditors), Mr. Mukund Kabra (Whole-time Director). - Appointment of Mr. Pradip Shah as an Independent Director. - Record Date for dividend is July 24, 2026, with payment on or after August 03, 2026.

- The 37th Annual General Meeting (AGM) will be held on Friday, July 31, 2026, via Video Conference. - The Record Date for ascertaining entitlement for the final Dividend of ₹1.35/- per Equity Share for FY26 is Friday, July 24, 2026. - If approved at the AGM, the dividend will be paid on or after August 03, 2026.

- The 37th Annual General Meeting (AGM) of Advanced Enzyme Technologies Ltd. will be held on Friday, July 31, 2026. - The Record Date for the final Dividend of ₹1.35/- per Equity Share for FY26 is Friday, July 24, 2026. - If approved at the AGM, the dividend will be paid on or after August 03, 2026.

- The trading window for the company's securities will be closed from July 01, 2026. - This closure is in anticipation of the announcement of financial results for the quarter ended June 30, 2026. - The window will remain closed until 48 hours after the results are announced.

- Ms. Rajshree Patel (DIN – 08761022) ceased to be an Independent Director of the Company. - The cessation is effective June 11, 2026, upon completion of her second consecutive term.

- Advanced Enzyme Technologies Ltd. made an additional investment of ₹2.5 million in its wholly-owned subsidiary, Advanced Nutrazyme Private Limited (ANPL). - This investment was through a rights issue for 2,50,000 Equity Shares of ₹10 each, increasing the total investment in ANPL to ₹3 million.

Advanced Enzyme Technologies reported strong FY26 performance, marking a turnaround from FY25 with broad-based growth across all segments. Management expects to maintain double-digit overall growth with steady margins, driven by increased productivity, efficiencies, and strategic R&D investments. A new R&D center in Nashik will be operational in H2 FY27, aiming to triple product development capacity. The company anticipates EU approval for anti-inflammatory products this year, presenting a significant market opportunity. Overall R&D CapEx for the year is projected around INR 130 crores. While acknowledging challenges in the US market and inflationary pressures, management aims to grow globally and will consider capacity expansion in a subsidiary this year.

Advanced Enzyme Technologies Ltd. announced that the audio recording of the conference call held on May 12, 2026, to discuss the Audited Financial Results for the quarter and year ended March 31, 2026, is available on the company's website. The transcript will be uploaded in due course.

Consolidated Revenue ₹2,034 Mn vs ₹1,672 Mn (▲22% YoY), EBITDA ₹632 Mn vs ₹456 Mn (▲39% YoY), PAT ₹453 Mn vs ₹267 Mn (▲69% YoY). EBITDA Margin 31% vs 27% (▲400bps).

Advanced Enzyme Technologies Ltd. board meeting on May 09, 2026, approved FY26 and Q4 FY26 consolidated financial results. A final dividend of ₹1.35 per equity share (67.5%) for FY26 was recommended, subject to AGM approval. The company deferred an interim dividend to preserve capital for strategic initiatives. The board also approved the re-appointment of Mr. Mukund Madhusudan Kabra as Whole Time Director and MSKA & Associates LLP as Statutory Auditors, and appointed Mr. Pradip Bhailal Shah as an Independent Director. Additionally, 49,350 ESOP shares were allotted.

Advanced Enzyme Technologies Ltd. board meeting on May 09, 2026, approved the annual and Q4 FY26 financial results and recommended a final dividend of ₹1.35 per equity share (67.5% on face value of ₹2) for FY 2025-26. The board deferred an interim dividend to preserve capital for future strategic actions. Key governance decisions included the re-appointment of Mr. Mukund Kabra as Whole Time Director, the appointment of Mr. Pradip Shah as an Independent Director, and the re-appointment of MSKA & Associates LLP as Statutory Auditors. The company also approved the allotment of 49,350 equity shares under its ESOP scheme. Auditors issued an unmodified opinion on the financial results.

The Board of Directors approved the Annual Financial Results for FY26 and Q4 FY26, and recommended a final dividend of ₹1.35 per equity share. An interim dividend was deferred to preserve capital for strategic evaluation. The Board also approved the re-appointment of Mr. Mukund Kabra as Whole Time Director and MSKA & Associates LLP as Statutory Auditors, and the appointment of Mr. Pradip Bhailal Shah as an Independent Director. Additionally, 49,350 equity shares were allotted under the ESOP Scheme.

Advanced Enzyme Technologies Ltd.'s board met on May 09, 2026, approving FY26 annual and Q4 financial results. The board recommended a final dividend of ₹1.35 per equity share (67.5%) for FY25-26, while deferring an interim dividend to preserve capital for strategic avenues. Key governance decisions included the re-appointment of Mr. Mukund Kabra as Whole-time Director, appointment of Mr. Pradip Bhailal Shah as an Independent Director, and re-appointment of MSKA & Associates LLP as Statutory Auditors. Additionally, 49,350 equity shares were allotted under ESOPs, increasing the company's paid-up capital.

Advanced Enzyme Technologies Ltd.'s Board Meeting on May 09, 2026, approved FY26 Annual Financial Results with an unmodified audit opinion. A final dividend of ₹1.35 per share (67.5%) was recommended, but an interim dividend was deferred to preserve capital for strategic initiatives. The Board re-appointed Mr. Mukund Kabra as Whole Time Director and MSKA & Associates LLP as Statutory Auditors. Mr. Pradip Shah was appointed as an Independent Director. Additionally, 49,350 equity shares were allotted under an ESOP scheme, increasing the company's paid-up share capital.

The Board of Directors of Advanced Enzyme Technologies Ltd. approved the annual financial results for the year ended March 31, 2026, and recommended a final dividend of ₹1.35 per equity share for FY 2025-26, subject to AGM approval. The Board deferred the declaration of an interim dividend to preserve capital for potential strategic avenues. Key governance decisions included the re-appointment of Mr. Mukund Madhusudan Kabra as Whole Time Director and MSKA & Associates LLP as Statutory Auditors, along with the appointment of Mr. Pradip Bhailal Shah as an Independent Director.

Consolidated Revenue ₹2,033.67Mn vs ₹1,671.79Mn (▲21.65% YoY), EBITDA ₹633.41Mn vs ₹456.02Mn (▲38.90% YoY), PAT ₹452.52Mn vs ₹267.28Mn (▲69.31% YoY). EBITDA Margin 31.15% vs 27.28% (▲387bps). The Board also recommended a final dividend of ₹1.35 per equity share for FY 2025-26.

Advanced Enzyme Technologies Limited announced on May 06, 2026, that CRISIL Ratings Limited has reaffirmed its credit ratings for total bank loan facilities of ₹100 Crore. The Long-Term Rating is reaffirmed at CRISIL A+/Stable, and the Short-Term Rating is reaffirmed at CRISIL A1+.

Advanced Enzyme Technologies Ltd. announced a conference call for analysts and investors to discuss the financial results for the quarter and year ended March 31, 2026. The call is scheduled for Tuesday, May 12, 2026, at 09:00 a.m. (IST) and will be attended by Mr. Mukund Kabra (Whole-time Director) and Mr. Beni Prasad Rauka (Chief Financial Officer).